Context Therapeutics (CNTX) Competitors

$2.60 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$2.64 +0.04 (+1.54%)

As of 05/22/2026 07:17 PM Eastern

CNTX vs. XNCR, EVMN, AMPH, LBRX, and VOR

Should you buy Context Therapeutics stock or one of its competitors? MarketBeat compares Context Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Context Therapeutics include Xencor (XNCR), Evommune (EVMN), Amphastar Pharmaceuticals (AMPH), LB Pharmaceuticals (LBRX), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry.

How does Context Therapeutics compare to Xencor?

Context Therapeutics (NASDAQ:CNTX) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Context Therapeutics currently has a consensus target price of $6.60, indicating a potential upside of 153.85%. Xencor has a consensus target price of $24.50, indicating a potential upside of 116.62%. Given Context Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Context Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Context Therapeutics has higher earnings, but lower revenue than Xencor. Context Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Xencor	$125.58M	6.68	-$91.92M	-$2.29	N/A

Context Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Xencor	-177.10%	-28.77%	-20.52%

Context Therapeutics has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Xencor has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

In the previous week, Xencor had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 3 mentions for Xencor and 1 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.66 beat Xencor's score of 0.56 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xencor	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

14.0% of Context Therapeutics shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by insiders. Comparatively, 4.8% of Xencor shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Context Therapeutics beats Xencor on 10 of the 14 factors compared between the two stocks.

How does Context Therapeutics compare to Evommune?

Context Therapeutics (NASDAQ:CNTX) and Evommune (NYSE:EVMN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

In the previous week, Context Therapeutics and Context Therapeutics both had 1 articles in the media. Context Therapeutics' average media sentiment score of 0.66 beat Evommune's score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

14.0% of Context Therapeutics shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Context Therapeutics presently has a consensus target price of $6.60, suggesting a potential upside of 153.85%. Evommune has a consensus target price of $49.25, suggesting a potential upside of 116.62%. Given Context Therapeutics' higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00

Context Therapeutics has higher earnings, but lower revenue than Evommune. Context Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Evommune	$13M	63.00	-$68.87M	-$9.50	N/A

Evommune's return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Evommune	N/A	N/A	N/A

Summary

Context Therapeutics and Evommune tied by winning 6 of the 12 factors compared between the two stocks.

How does Context Therapeutics compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Context Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Context Therapeutics	N/A	-59.95%	-54.78%

Amphastar Pharmaceuticals presently has a consensus target price of $24.50, indicating a potential upside of 33.08%. Context Therapeutics has a consensus target price of $6.60, indicating a potential upside of 153.85%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Amphastar Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

In the previous week, Amphastar Pharmaceuticals and Amphastar Pharmaceuticals both had 1 articles in the media. Context Therapeutics' average media sentiment score of 0.66 beat Amphastar Pharmaceuticals' score of 0.46 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals has higher revenue and earnings than Context Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.13	$98.09M	$1.66	11.09
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A

Summary

Amphastar Pharmaceuticals beats Context Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Context Therapeutics compare to LB Pharmaceuticals?

Context Therapeutics (NASDAQ:CNTX) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Context Therapeutics presently has a consensus price target of $6.60, suggesting a potential upside of 153.85%. LB Pharmaceuticals has a consensus price target of $38.40, suggesting a potential upside of 36.56%. Given Context Therapeutics' higher probable upside, research analysts clearly believe Context Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

14.0% of Context Therapeutics shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A

LB Pharmaceuticals' return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
LB Pharmaceuticals	N/A	N/A	N/A

In the previous week, Context Therapeutics and Context Therapeutics both had 1 articles in the media. Context Therapeutics' average media sentiment score of 0.66 beat LB Pharmaceuticals' score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LB Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Context Therapeutics beats LB Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Context Therapeutics compare to Vor Biopharma?

Context Therapeutics (NASDAQ:CNTX) and Vor Biopharma (NASDAQ:VOR) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Vor Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Context Therapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

Context Therapeutics presently has a consensus target price of $6.60, indicating a potential upside of 153.85%. Vor Biopharma has a consensus target price of $42.25, indicating a potential upside of 194.84%. Given Vor Biopharma's higher probable upside, analysts clearly believe Vor Biopharma is more favorable than Context Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Vor Biopharma had 8 more articles in the media than Context Therapeutics. MarketBeat recorded 9 mentions for Vor Biopharma and 1 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.66 beat Vor Biopharma's score of 0.64 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vor Biopharma's return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Vor Biopharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Summary

Vor Biopharma beats Context Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Context Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTX vs. The Competition

Export

Metric	Context Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$238.89M	$3.03B	$6.43B	$12.32B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	N/A	17.79	21.01	25.66
Price / Sales	N/A	784.72	615.84	111.99
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	4.56	5.86	10.37	7.14
Net Income	-$36.12M	$74.99M	$3.57B	$335.98M
7 Day Performance	20.93%	2.55%	6.01%	3.56%
1 Month Performance	15.04%	-3.05%	3.52%	2.54%
1 Year Performance	275.23%	34.38%	34.13%	35.05%

Context Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTX Context Therapeutics	3.1434 of 5 stars	$2.60 flat	$6.60 +153.8%	+275.2%	$238.89M	N/A	N/A	7	Gap Down High Trading Volume
XNCR Xencor	2.0182 of 5 stars	$10.51 -5.0%	$24.50 +133.1%	+49.4%	$780.18M	$125.58M	N/A	280
EVMN Evommune	2.8305 of 5 stars	$21.61 -1.3%	$49.25 +128.0%	N/A	$778.21M	$13M	N/A	45	Gap Up
AMPH Amphastar Pharmaceuticals	4.1092 of 5 stars	$17.66 +2.7%	$24.50 +38.7%	-24.8%	$777.75M	$719.89M	10.63	1,976
LBRX LB Pharmaceuticals	1.6501 of 5 stars	$26.84 -3.3%	$38.40 +43.1%	N/A	$769.63M	N/A	N/A	16	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTX) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Context Therapeutics (CNTX) Competitors

CNTX vs. XNCR, EVMN, AMPH, LBRX, and VOR

How does Context Therapeutics compare to Xencor?

Summary

How does Context Therapeutics compare to Evommune?

Summary

How does Context Therapeutics compare to Amphastar Pharmaceuticals?

Summary

How does Context Therapeutics compare to LB Pharmaceuticals?

Summary

How does Context Therapeutics compare to Vor Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Context Therapeutics (CNTX) Competitors

CNTX vs. XNCR, EVMN, AMPH, LBRX, and VOR

How does Context Therapeutics compare to Xencor?

Do analysts prefer CNTX or XNCR?

Which has higher valuation and earnings, CNTX or XNCR?

Is CNTX or XNCR more profitable?

Which has more risk & volatility, CNTX or XNCR?

Does the media refer more to CNTX or XNCR?

Do insiders and institutionals hold more shares of CNTX or XNCR?

Summary

How does Context Therapeutics compare to Evommune?

Does the media prefer CNTX or EVMN?

Do institutionals and insiders have more ownership in CNTX or EVMN?

Do analysts prefer CNTX or EVMN?

Which has preferable valuation & earnings, CNTX or EVMN?

Is CNTX or EVMN more profitable?

Summary

How does Context Therapeutics compare to Amphastar Pharmaceuticals?

Is AMPH or CNTX more profitable?

Do analysts rate AMPH or CNTX?

Which has more risk and volatility, AMPH or CNTX?

Does the media refer more to AMPH or CNTX?

Do institutionals & insiders believe in AMPH or CNTX?

Which has higher earnings & valuation, AMPH or CNTX?

Summary

How does Context Therapeutics compare to LB Pharmaceuticals?

Do analysts rate CNTX or LBRX?

Do institutionals & insiders believe in CNTX or LBRX?

Which has better earnings and valuation, CNTX or LBRX?

Is CNTX or LBRX more profitable?

Does the media favor CNTX or LBRX?

Summary

How does Context Therapeutics compare to Vor Biopharma?

Do institutionals and insiders believe in CNTX or VOR?

Which has more risk and volatility, CNTX or VOR?

Do analysts recommend CNTX or VOR?

Does the media refer more to CNTX or VOR?

Is CNTX or VOR more profitable?

Which has preferable earnings & valuation, CNTX or VOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools